WO2024036232A3 - Bispecific antibodies and uses thereof - Google Patents

Bispecific antibodies and uses thereof Download PDF

Info

Publication number
WO2024036232A3
WO2024036232A3 PCT/US2023/071960 US2023071960W WO2024036232A3 WO 2024036232 A3 WO2024036232 A3 WO 2024036232A3 US 2023071960 W US2023071960 W US 2023071960W WO 2024036232 A3 WO2024036232 A3 WO 2024036232A3
Authority
WO
WIPO (PCT)
Prior art keywords
pigr
antibody
binding domain
transcytosis
fragment
Prior art date
Application number
PCT/US2023/071960
Other languages
French (fr)
Other versions
WO2024036232A2 (en
Inventor
Jose CONEJO-GARCIA
Subir Biswas
Original Assignee
H. Lee Moffitt Cancer Center And Research Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lee Moffitt Cancer Center And Research Institute, Inc. filed Critical H. Lee Moffitt Cancer Center And Research Institute, Inc.
Publication of WO2024036232A2 publication Critical patent/WO2024036232A2/en
Publication of WO2024036232A3 publication Critical patent/WO2024036232A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

Disclosed are bi-specific antibodies that bind an oncogene-binding domain and an α-PIGR binding domain. As disclosed herein, the α-PIGR binding domain facilitates translocation of the antibody from the cell membrane into the cytosol. Binding of the antibody to PIGR on the cell surface causes the antibody to be trafficked in endosomes through a process termed transcytosis, until it reaches the cell membrane on a different pole, where a fragment of PIGR is cleaved. This results in a complex consisting of the bi-specific antibody, a fragment of PIGR (now termed the secretory component), and any antigen they encountered through transcytosis.
PCT/US2023/071960 2022-08-09 2023-08-09 Bispecific antibodies and uses thereof WO2024036232A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263370798P 2022-08-09 2022-08-09
US63/370,798 2022-08-09
US202263396948P 2022-08-10 2022-08-10
US63/396,948 2022-08-10

Publications (2)

Publication Number Publication Date
WO2024036232A2 WO2024036232A2 (en) 2024-02-15
WO2024036232A3 true WO2024036232A3 (en) 2024-03-21

Family

ID=89852544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071960 WO2024036232A2 (en) 2022-08-09 2023-08-09 Bispecific antibodies and uses thereof

Country Status (1)

Country Link
WO (1) WO2024036232A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046100A1 (en) * 1996-06-03 1997-12-11 Case Western Reserve University Serpin enzyme complex receptor-mediated gene transfer
US20160145336A1 (en) * 2014-11-26 2016-05-26 Adventist Health System/Sunbelt Inc. Effector-deficient anti-cd32a antibodies
WO2021245184A1 (en) * 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046100A1 (en) * 1996-06-03 1997-12-11 Case Western Reserve University Serpin enzyme complex receptor-mediated gene transfer
US20160145336A1 (en) * 2014-11-26 2016-05-26 Adventist Health System/Sunbelt Inc. Effector-deficient anti-cd32a antibodies
WO2021245184A1 (en) * 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Platform Technology: Dimeric IgA for intra-tumoral targeting of mutant KRAS ", MOFFITT CANCER CENTER, 26 January 2022 (2022-01-26), XP093152788, Retrieved from the Internet <URL:https://www.moffitt.org/contentassets/62c8a53c449e476598598d41050db2cf/21mb061-iga-targeting-mutant-kras-tom.pdf> *

Also Published As

Publication number Publication date
WO2024036232A2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
WO2010046775A3 (en) Methods for producing antibodies from plasma cells
EP4257611A3 (en) Anti-muc1 antibody
IN2012DN02535A (en)
WO2008006235A3 (en) Scfv antibodies which pass epithelial and/or endothelial layers
WO2008120202A3 (en) Antibodies, methods and kits for diagnosing and treating melanoma
WO2013024059A3 (en) Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
JP2011510654A5 (en)
WO2009010539A3 (en) Receptor for interleukin-6 (il-6) from macaca fascicularis
WO2011022077A3 (en) A nucleic acid cassette for producing recombinant antibodies
ATE554390T1 (en) METHOD FOR OBTAINING ANTIBODIES
MX2022006230A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom.
WO2011108008A3 (en) Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
WO2021207242A3 (en) Anti-mesothelin antigen-binding molecules and uses thereof
Okazaki et al. Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment V HH against EGFR
MX2020013606A (en) Multi-specific antibody constructs.
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
WO2024036232A3 (en) Bispecific antibodies and uses thereof
WO2022047424A8 (en) Compositions and methods for delivery of nucleic acids to cells
MX2023006969A (en) Gucy2c binding molecules and uses thereof.
MX2022003833A (en) Anti-kir3dl3 antibodies and uses thereof.
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
MX2023007583A (en) Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same.
AR126759A2 (en) ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
WO2022081460A8 (en) Biosynthetic materials and methods for multidirectional biotransportation
WO2020166810A3 (en) Antibody fragment consisting only of constant regions of antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853519

Country of ref document: EP

Kind code of ref document: A2